Compare Merck & Co., Inc. (MRK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs TG Therapeutics Inc — how do they compare? Merck & Co., Inc. trades at $146.05 (market cap $351.28B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Merck & Co., Inc. is far larger — about 43× TG Therapeutics Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and TG Therapeutics Inc for 16 Days on average.
| MRK | TGTX | |
|---|---|---|
Market Cap | $351.28B | $8.16B |
Volume | 7,969,665 | 1,735,121 |
Sector | Health | Health |
52-Week High | $156.43 | $59.06 |
52-Week Low | $82.49 | $26.94 |
Typical Hold Time | 98 Days | 16 Days |
Enterprise Value | $398.04B | $8.37B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
